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Age-Dependent Decline in -Cell Proliferation Restricts
the Capacity of -Cell Regeneration in Mice
Shuen-Ing Tschen,1 Sangeeta Dhawan,1 Tatyana Gurlo,1 and Anil Bhushan1,2
OBJECTIVE—The aim of this study was to elucidate whether
age plays a role in the expansion or regeneration of -cell mass.
RESEARCH DESIGN AND METHODS—We analyzed the ca-
pacity of -cell expansion in 1.5- and 8-month-old mice in
response to a high-fat diet, after short-term treatment with the
glucagon-like peptide 1 (GLP-1) analog exendin-4, or after strep-
tozotocin (STZ) administration.
RESULTS—Young mice responded to high-fat diet by increasing
-cell mass and -cell proliferation and maintaining normoglyce-
mia. Old mice, by contrast, did not display any increases in -cell
mass or -cell proliferation in response to high-fat diet and
became diabetic. To further assess the plasticity of -cell mass
with respect to age, young and old mice were injected with a
single dose of STZ, and -cell proliferation was analyzed to
assess the regeneration of -cells. We observed a fourfold
increase in -cell proliferation in young mice after STZ adminis-
tration, whereas no changes in -cell proliferation were observed
in older mice. The capacity to expand -cell mass in response to
short-term treatment with the GLP-1 analog exendin-4 also
declined with age. The ability of -cell mass to expand was
correlated with higher levels of Bmi1, a polycomb group protein
that is known to regulate the Ink4a locus, and decreased levels
of p16Ink4a expression in the -cells. Young Bmi1/ mice that
prematurely upregulate p16Ink4a failed to expand -cell mass in
response to exendin-4, indicating that p16Ink4a levels are a critical
determinant of -cell mass expansion.
CONCLUSIONS—-Cell proliferation and the capacity of
-cells to regenerate declines with age and is regulated by the
Bmi1/p16Ink4a pathway. Diabetes 58:1312–1320, 2009
Hyperglycemia in type 1 and 2 diabetes is, bydefinition, caused by insufficient insulin secre-tion to meet insulin demand. Defective insulinsecretion in both forms of diabetes is caused in
part by loss of -cell mass (1–4). Diabetes can be reversed
in type 1 and 2 diabetes by replacement of -cell mass, as
demonstrated by pancreas and islet transplantation (5,6).
However, given the shortage of organ donors and the need
for chronic immunosuppression, pancreas transplantation
has limited applicability in the treatment of diabetes.
Regeneration of -cell mass is one promising approach
to replace the deficit in -cell mass in diabetic patients.
Regeneration occurs in rodents after injury or genetic
ablation of -cells (7). Lineage tracing experiments show
that new -cells can arise from proliferation of preexisting
-cells (8). However, both the capacity of regeneration and
the mechanism involved can differ significantly depending
on the experimental model. An alternative source of
-cells has recently been proposed showing that faculta-
tive progenitors can be found in regenerating pancreatic
ducts (9). Several studies have shown that the endocrine
pancreas has endogenous renewal capacity in response to
metabolic demands such as pregnancy and insulin resis-
tance (10). Changes in insulin demand caused by physio-
logical states such as insulin resistance have been shown
to lead to adaptive changes in -cell mass. The cell source
and mechanism leading to the endogenous renewal is not
clear, although proliferation of -cells appears to play an
important role (11). Elucidating mechanisms of regenera-
tion and endogenous renewal in response to metabolic
demands may provide novel insights into approaches to
restore functional -cell mass in diabetes.
Most of the studies exploring the capacity of endoge-
nous renewal have been carried out on rodents at rela-
tively young ages, and several studies suggest that the
capacity to expand or regenerate -cell mass may decline
with age. For example, a threefold increase of insulin
content was measured in the residual pancreas after 90%
pancreatectomy in 1-month-old rats; however, a compara-
ble increase was not observed in rats that were 5 or 15
months old (12). Moreover, consistent with the adaptive
increase in pancreatic insulin content in the 1-month-old
but not older animals after a 90% pancreatectomy, blood
glucose values in the 1-month-old rats declined 2 weeks
after surgery, whereas no such decline was observed in 5-
and 15-month-old rats (12). The rate of -cell proliferation
gradually declines with aging in rats to a steady state by 7
months of age (13). Furthermore, long-term bromodeoxyuri-
dine labeling in 1-year-old mice also suggests that -cell
replication rates decline with age (14). The decline in -cell
proliferation with age correlates with increased expression
of the cell cycle regulator p16Ink4a in islet cells (15). p16Ink4a
inhibits the cyclin-dependent kinase 4 (CDK4)-cyclin D2
complex and can inhibit cell cycle progression and regener-
ation of islet cells. Transgenic mice that overexpressed
p16Ink4a showed reduced islet cell proliferation and a reduc-
tion in the regenerative capacity of islets after toxin-mediated
destruction. However, the mechanisms that regulate the
increase in p16Ink4a with aging are not known.
Establishing the basis of aging in affecting the capacity
of adaptive changes in -cell mass in adult humans versus
young rodents has important clinical implications. If it is a
species difference, then caution will need to be exercised
extrapolating findings in rodents to the potential for -cell
regeneration in humans. For example, partial pancreatec-
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tomy in young mice is followed by extensive regeneration
of -cells through -cell replication. In contrast, partial
pancreatecomy in adult humans does not lead to -cell
regeneration (16). To date, it is not clear whether this
different outcome is a species difference or a consequence
of partial pancreatectomy at different ages. Also of inter-
est, genetically obese mice have a several-fold increase in
-cell mass, whereas obese adult humans have only a
much more modest 0.5-fold increase in -cell mass (1).
Again, it is not known whether this is a species difference
or the consequence of a different response to obesity-
induced insulin resistance during aging.
Studies to date that have reported an increase in -cell
mass with glucagon-like peptide 1 (GLP-1)-1 based thera-
pies were undertaken in young rodents (17–21). On the
strength of those observations, it has been proposed that
these therapies might serve to foster -cell regeneration in
humans with either type 1 or type 2 diabetes (22–25).
However, it is plausible that GLP-1–induced expansion of
-cell mass may only be achievable in young subjects.
Similarly, the rapid regeneration of -cell mass in young
mice after a single dose of the -cell toxin streptozotocin
(STZ) has been widely used as a model for -cell regener-
ation in type 1 diabetes, but it is not yet known whether
there is comparable recovery of -cell mass in mice during
the adult phase of -cell turnover, a circumstance more
clinically relevant to most humans.
In the current studies, the capacity of endogenous
renewal of -cells in response to either a high-fat diet or
the GLP-1 analog exendin-4 as well as the capacity to
regenerate after toxin administration was examined in
young and old mice. -Cell mass and metabolic measure-
ments were measured after high-fat diet or exendin-4
treatment. -Cell proliferation was measured to probe the
mechanism by which age could affect the capacity for
-cell renewal. Furthermore, the levels of p16ink4a were
linked to the capacity of -cell proliferation. Because
several studies have established a role for the polycomb
group protein Bmi1 in the regulation of p16Ink4a (26–28),
we analyzed the levels of Bmi1. We further showed that
loss of Bmi1 results in premature increase in the expres-
sion of p16ink4a. Because aging can lead to many changes
in the -cell other than p16Ink4a upregulation, we used
Bmi1 knockout mice as a model to explore the endoge-
nous capacity to renew in young mice in which p16ink4a is
prematurely upregulated. This result indicates that levels
of p16ink4a are the primary determinant of the capacity to
expand -cell mass. Our data suggest that the older mice,
unlike younger mice, have a limited capacity to expand
-cell mass because of age-related accumulation of
p16Ink4a.
RESEARCH DESIGN AND METHODS
We obtained 6-week-old (young) and 7- to 8-month-old (old) male C57BL/6
mice from The Jackson Laboratory. For the high-fat diet experiment, 12 young
or 12 old mice were fed with either normal diet (4.4% of total calories derived
from fat, 3.9 kcal/g; Harlan Teklad) or high-fat diet (55% of total calories
derived from fat, 4.8 kcal/g; Harlan Teklad) for 8 weeks. For exendin-4
experiments, six young and six old mice were injected intraperitoneally with
either exendin-4 (10 nmol/kg; Sigma) or PBS for 7 days. For the STZ
(Sigma-Aldrich) experiment, six young and six old mice were injected with a
single dose of 90 mg/kg freshly prepared STZ in citrate buffer (pH 4.5) and
killed at 7 days. Bmi1/ mice were obtained from Maarten van Lohuizen of
the Netherlands Cancer Institute. For Bmi1/ mice, targeted disruption of
the Bmi1 allele has been described before (29). The animals were maintained
by mating Bmi1/ males and females on a C57BL/6J background. Mice were
fed ad libitum on standard diet and keep under a 12-h light/dark circle. All
animal protocols were approved by the chancellor’s animal research commit-
tee at the University of California, Los Angeles.
Metabolic analysis. Fasting blood glucose was measured after overnight
fasting. An insulin tolerance test was performed after a 6-h fast. Blood glucose
was measured before intraperitoneal injection of insulin (0.75 mU/g body wt)
and then 20, 40, and 60 min after injection. No anesthesia was used during the
experiment. Glucose tolerance testing was performed after overnight fasting.
Blood glucose levels (mg/dl) were measured before intraperitoneal injection
of glucose (2 mg dextrose/g body wt) and then 15, 30, 60, and 120 min after
injection.
Immunohistochemistry. Pancreatic tissue was processed as previously
described (11). In brief, the pancreas was dissected and fixed in 4% formal-
dehyde before being embedded in paraffin. Then, 5-m sections were depar-
affinized and rehydrated, followed by antigen retrieval using antigen
unmasking buffer (Vector Labs), and then permeabilized in 0.4% Triton
X-100/Tris-buffered saline. Slides were blocked with 3% IgG-free BSA (Jackson
ImmunoResearch Laboratories) and treated with anti-mouse insulin (Dako),
anti-ki67 (BD Pharmingen), anti–proliferating cell nuclear antigen (PCNA; Lab
Vision), anti-Bmi1 (Millipore), anti-p16Ink4a (Santa Cruz), anti–cyclin D2
(Santa Cruz), or anti-p27 (Santa Cruz) antibody followed by fluorescein
isothiocyanate– or Cy3-conjugated secondary antibodies (The Jackson Labo-
ratory). Terminal deoxynucleotidyl transferase dUTP nick-end labeling
(TUNEL) assay was detected using an in situ cell death detection kit (Roche)
according to manufacturer’s instructions. Slides were mounted with Vecta-
shield with 46-diamidino-2-phenylindole (Vector Labs), and images were
obtained with a Leica DM6000 microscope using Openlab software (Improvi-
sion). The immunofluorescence data presented are representatives of at least
five animals per group in each case.
-Cell mass. -Cell mass was measured as previously described (11). In brief,
five to eight sections from each pancreas were stained with anti-mouse insulin
antibody (Dako) and scanned by a Leica DM6000 microscope. Montage images
were made by ImageJ software. The cross-sectional areas of pancreas and
-cells were determined by ImagePro software. -Cell mass per pancreas was
estimated as the product of the relative cross-sectional area of -cells per total
tissue and the weight of the pancreas and was calculated by examining
pancreata from at least three animals for each genotype.
Islet isolation and immunoblotting. Liberase propidium iodide–purified
enzyme blend for rodent islet isolation (Roche) was infused at 3.5 mg/ml into
the pancreas via the bile duct. Inflated pancreata were then removed and
incubated in Liberase propidium iodide for 18 min at 37°C. Islets were
dissociated from the exocrine tissues by shaking vigorously several times,
followed by Histopaque (Sigma-Aldrich) gradient. Islets were handpicked
under a dissecting microscope and lysed by tissue extraction buffer (Invitro-
gen). Lysates with equal amounts of protein were resolved by SDS-PAGE,
followed by transferring to polyvinylidene fluoride membrane for immuno-
blotting. The membranes were probed with specific antibodies against p16Ink4a
(Santa Cruz), Bmi1 (Millipore), and -tubulin (Sigma-Aldrich). The data
presented are representative of at least three experiments.
Chromatin immunoprecipitation. We performed chromatin immunopre-
cipitation (ChIP) analysis using a Millipore ChIP kit (no. 17-295) according to
the manufacturer’s instructions, with minor modifications. The islets (150–200
islets per group) were treated with 2% paraformaldehyde at room temperature
for 20 min to cross-link the DNA with bound proteins. After washing, the islets
were resuspended in SDS lysis buffer with protease inhibitors and sonicated
to shear the chromatin. The chromatin was then precleared and incubated
with 2–5 mg of anti–acetyl histone H3 lysine 9 (H3K9; no. 07-532; Millipore), or
normal mouse IgG as a control, overnight at 4°C with agitation. After
immunoprecipitation, the chromatin was harvested, the cross-links were
reversed, and the DNA was purified and precipitated. The resulting DNA was
quantified and served as a template for the real-time PCR, performed using a
LightCycler FastStartPLUS DNA SYBR Master kit (Roche) and Light Cycler
PCR equipment (Roche). The DNA enrichment after ChIP was estimated as
the percentage bound-to-input ratio, determined by real-time PCR. The
primers used to amplify the Ink4a/Arf locus are as follows: primer set 1:
forward 5GAGTACAGCAGCGGGAGCAT-3, reverse 5-GAACTTCACCAA
GAAAACCCTCTCT-3; primer set 2: forward 5-GTCCGATCCTTTAGCGCT
GTT-3, reverse 5-AGCCCGGACTACAGAAGAGATG-3; primer set 3:
5CCGGAGCCACCCATTAAACTA-3, reverse 5-CAAGACTTCTCAAAAATAA
GACACTGAAA-3; primer set 4: forward 5-CCCAACACCCACTTGAGGAA-3,
reverse 5-CAGAGGTCACAGGCATCGAA-3; and primer set 5: (negative con-
trol, HoxC13 exon 2) forward 5-CATTTTTCACTGATTTCCTAAGCA-3, re-
verse 5-CAATGATGTCACCCCTCCTC-3.
Cell culture and transfection. Min6 cells were maintained in Dulbecco’s
modified Eagle’s medium with 10% fetal bovine serum and transfected using
Lipofectamine 2000 (Invitrogen) following the manufacturer’s instructions
with 1 mg of Bmi1 construct (in pcDNA3 myc-HisA, resulting in expression of
NH2-terminal myc-tagged Bmi1) and the control enhanced green fluorescent
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protein construct (in pcDNA3), allowing expression from the cytomegalovirus
promoter in either case.
Statistical analyses. All data were expressed as the means  SE. Mean and
SE values were calculated from at least triplicates of a representative
experiment. The statistical significance of differences was measured by
unpaired Student’s t test and confirmed by one-way ANOVA for repeat
measures. P  0.05 indicated statistical significance. The P values indicated in
the graphs are from Student’s t test.
RESULTS
Adaptive expansion of -cell mass associated with
insulin resistance is age dependent. To ascertain
whether age plays a role in the adaptive -cell mass
expansion associated with insulin resistance, young (6-
week-old) and old (7- to 8-month-old) mice were fed a
high-fat diet. Insulin tolerance testing performed after 8
weeks of high-fat diet showed that both young and old
mice displayed decreased insulin sensitivity compared
with mice on a normal diet (Fig. 1A). No statistically
significant difference in body weight between groups was
noted at the beginning of the study. The body weight of
both young and old mice showed a 50% increase after 8
weeks of high-fat diet (data not shown). Glucose tolerance
tests showed that blood glucose levels of old mice after 8
weeks of high-fat diet remained 400 mg/dl by the end of
the 120-min testing period. By contrast, young mice after 8
weeks of high-fat diet reached baseline by the end of the
120-min testing period (Fig. 1B). Measurement of fasting
blood glucose revealed that older mice displayed fasting
blood glucose levels consistently200 mg/dl after 8 weeks
of high-fat diet, indicating that these mice were unable to
maintain glucose homeostasis (Fig. 1C). In contrast, young
mice fed a high-fat diet did not show fasting blood glucose
levels that were significantly different from young mice fed
a normal diet.
The inability of old mice, unlike young mice, after 8
weeks of high-fat diet to maintain glucose homeostasis led
us to analyze whether the adaptive expansion of -cell
mass associated with insulin resistance differed in the
different age-groups. Young mice after 8 weeks of high-fat
diet showed a fivefold increase in -cell mass compared
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FIG. 1. Old mice failed to compensate diet-induced insulin resistance and developed diabetes after an 8-week high-fat diet. Young (6-week-old)
and old (7-month-old) mice were fed normal diet (ND; 12.2% calories from fat) or high-fat diet (HFD; 55% calories from fat) for 8 weeks. A:
Insulin tolerance test in young and old mice after 8 weeks of high-fat diet or normal diet (n 6 in each group). Mice were fasted 6 h before testing.
High-fat diet–fed mice were compared with normal diet–fed mice. **P < 0.005 (60 min). B: Glucose tolerance test in young and old mice after 8
weeks of high-fat diet or normal diet feeding. Mice were fasted overnight, and the blood glucose level was measured before and after glucose
challenge. **P < 0.005. C: Blood glucose levels after overnight fasting. High-fat diet–fed mice were compared with normal diet–fed mice. **P <
0.005. D: Analysis of -cell mass of young and old mice after 8 weeks of normal diet or high-fat diet feeding. Values are representative of 5–6 slides
spanning the whole pancreas of each mouse and three mice per group. **P < 0.005.
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with the normal-diet group. In contrast, old mice fed
high-fat diet did not show any changes in -cell mass
compared with control old mice (Fig. 1D). Moreover,
pancreas weight did not show any significant increase
after 8 weeks of high-fat diet in both young and old mice
(data not shown). Thus, young mice, unlike old mice, have
the capacity to expand -cell mass to adapt to insulin
resistance.
Expansion of -cell mass is correlated with p16Ink4a
levels in the -cells. To analyze whether increased
proliferation could account for the expansion of -cell
mass in young mice fed a high-fat diet, the number of Ki67-
and PCNA-positive -cells was quantified in mice fed
high-fat diet and those fed normal diet. A 7.5-fold increase
of Ki67-positive -cells and a 2.3-fold increase of PCNA-
positive -cells was observed in the young mice fed
high-fat diet compared with the control group. In contrast,
the number of Ki67- and PCNA-positive -cells did not
change in old mice after a high-fat diet compared with
those fed normal diet (Fig. 2A and B). No TUNEL staining
(as a measure of apoptosis) was observed in all groups
(data not shown). Because decreased proliferative capac-
ity has been correlated with increased expression of
p16Ink4a with age (15), we determined the levels of p16Ink4a
in isolated islets from mice of increasing age. As shown in
Fig. 2C, p16Ink4a levels increase with age in isolated islets.
Immunohistochemistry revealed that -cells of 1-month-
old mice showed little expression of p16Ink4a, in contrast
to high levels of p16Ink4a in 6-month-old mice (Fig. 2D). To
determine whether p16 levels played a role in the adaptive
expansion of -cell mass in response to high-fat diet, we
isolated islets from young and old mice fed normal diet or
high-fat diet and measured p16ink4a levels by Western blot.
In islets isolated from young mice, low levels of p16ink4a
were apparent, which decreased after 8 weeks of high-fat diet
feeding. In contrast, high levels of p16Ink4a in islets from old
mice did not change with high-fat diet (Fig. 2E). We next
examined whether levels of Bmi1, a polycomb group protein
that is known to regulate the Ink4a locus, were also affected.
High Bmi1 levels were apparent in islets isolated from young
mice, and increased levels of Bmi1 were apparent after
high-fat diet. In contrast, islets isolated from old mice did not
show appreciable levels of Bmi1.
Aging affects the glucoincretin exendin-4–induced
-cell mass expansion. Glucoincretin hormones GLP-1
and its long-acting peptide analogue exendin-4 have been
suggested to induce -cell mass expansion by increasing
-cell proliferation (30). A 1-week daily injection of ex-
endin-4 resulted in a twofold increase in -cell mass (30).
To further investigate the effect of aging on -cell mass
expansion and -cell proliferation, young and old mice were
injected intraperitoneally with exendin-4 daily for 7 days, and
-cell mass was analyzed. After exendin-4 treatment, -cell
mass in young mice showed a twofold increment compared
with control group injected with PBS. In contrast, old mice
treated with exendin-4 did not show any increases in their
-cell mass (Fig. 3A). These data suggest that as adaptive
expansion associated with insulin resistance, the capacity of
-cell mass to expand in response to glucoincretin hormones
challenge is severely diminished with aging.
To analyze whether increased proliferation could ac-
count for the expansion of -cell mass in young mice
treated with exendin-4, the number of Ki67- and PCNA-
positive -cells was quantified. A 4-fold increase of Ki67-
positive -cells and a 5.5-fold increase of PCNA-positive
-cells was observed in the young mice treated with
exendin-4 compared with the control group. In contrast,
the number of Ki67- and PCNA-positive -cells did not
change in old mice after treatment with exendin-4 com-
pared with untreated old mice (Fig. 3B and C). We next
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FIG. 2. Increased -cell proliferation in high-fat diet young mice
correlates with increased Bmi1 levels. A: Percentage of Ki67-positive
-cells of young and old mice after 8 weeks of normal diet or high-fat
diet feeding. Values are averaged from three slides for each mouse and
three mice for each group. ***P < 0.005. B: Percentage of PCNA-
positive -cells of young and old mice after 8 weeks of normal diet or
high-fat diet feeding. Values are averaged from three slides for each
mouse and three mice in each group. **P< 0.05 for young mice fed normal
diet vs. young mice fed high-fat diet. C: Protein levels of p16 in isolated
islets from 1-, 4-, 6-, and 11-month-old mice. Data were representative of
pooled islets from 3–5 mice per group. D: Representative picture of
pancreatic sections from 1- and 6-month-old wild-type mice stained with
antibodies to p16 (red) and insulin (green). E: Levels of p16 and Bmi1
protein expression in the pooled islet cells isolated from 3–4 normal diet
or high-fat diet young and old pancreata. Data were representative of
pooled islets from 3–4 mice per group. Graph demonstrates densitometric
analysis of immunoblot of p16 and Bmi1 normalized to -tubulin. For all
panels, data are representative of three experiments. **P < 0.05 for
high-fat diet young mice vs. high-fat diet old mice. HFD, high-fat diet; ND,
normal diet; Tub, -tubulin. (A high-quality digital representation of this
figure is available in the online issue).
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examined whether the failure of old mice to expand their
-cell mass on exendin-4 treatment is dependent on levels
of p16Ink4a. A marked decline of p16Ink4a expression levels
was observed in islets of young mice (Fig. 3D and E),
which is concomitant with increased Bmi1 levels (Fig. 3H
and I). In contrast, exendin-4 treatment did not lead to a
decrease of p16Ink4a levels in the -cells in the old mice
(Fig. 3F and G). Furthermore, levels of Bmi1 (Fig. 3J and
K) did not show much difference between the exendin-4–
treated mice and the PBS control group.
We first assessed whether p16Ink4a was a specific cell
cycle target of Bmi1 by analyzing expression levels of
p16Ink4a along with other cell cycle regulators involved in
-cell proliferation. Immunohistochemistry analysis of
pancreatic sections from 14-day-old Bmi1/ mice and
wild-type littermates showed p16Ink4a was upregulated in
islets of Bmi1/ mice (Fig. 4). Other cell cycle targets
cyclin D2 and p27 were unaffected by the absence of Bmi1
(Fig. 4). To directly test whether Bmi1 regulates p16Ink4a,
we measured the levels of p16Ink4a in islets isolated from
4-week-old wild-type and Bmi1/ mice. Immunoblots
showed increased levels of p16Ink4a in islets isolated from
Bmi1/ mice (Fig. 5A). To further confirm whether Bmi1
represses p16Ink4a, we generated an expression vector that
allowed expression of Bmi1 fused with an NH2-terminal
myc tag. The expression of myc-tagged Bmi1 in the Min6
cells resulted in reduced levels of p16Ink4a protein, thus
confirming the repressive effect of Bmi1 on p16Ink4a ex-
pression (Fig. 5B). We next assessed whether Bmi1 regu-
lated p16Ink4a expression by affecting the chromatin
structure of the Ink4a/Arf locus that encodes p16Ink4a. We
determined whether histone acetylation at the Ink4a/Arf
locus, which results in the loosening of chromatin and
lends itself to transcription, was regulated by Bmi1. We
examined the levels of H3K9 acetylation associated with
the Ink4a/Arf locus in islets isolated from 6-week-old
Bmi1/ mice and their wild-type littermates. In the
absence of Bmi1, the levels of H3K9 acetylation were
increased, suggesting that Bmi1 mediated repression of
p16Ink4a via modulation of chromatin structure (Fig. 5C).
The absence of Bmi1 in young mice, which results in
premature increase in p16Ink4a expression in the -cells,
0
1
2
B
et
a 
ce
ll 
m
as
s 
(m
g)
Pe
rc
en
t K
i6
7+
 c
el
ls
Pe
rc
en
t P
C
N
A
+  
ce
lls
3
4
** **
PBS
Ex-4
PBS
Ex-4
PBS
Ex-4
0
2
4
6
8
10
12
14
0
1
2
3
4
Young OldYoung Old Young Old
A
PBS
p16
Bmi1
Extendin-4 PBS Extendin-4
Young Old
D E F G
H I J K
B C
***
FIG. 3. Increased Bmi1 and decreased p16 levels are coincident with adaptive -cell mass expansion on exendin-4 treatment in young mice. A:
Analysis of -cell mass of young and old mice after 7 days’ constitutive injection of exendin-4. Values are representative of five slides spanning
the whole pancreas of each mouse and three mice per group. B: Percentage of Ki67-positive -cells of young and old mice after 7 days of PBS or
exendin-4 treatment. Values are averaged from slides for each mouse and three mice in each group. **P < 0.05. C: Percentage of PCNA-positive
-cells of young and old mice after 7 days of PBS or exendin-4 treatment. Values are averaged from slides for each mouse and three mice in each
group. ***P < 0.005 comparing PBS– vs. exendin-4–treated groups. D–K: Pancreatic sections from young (D, E, H, and I) and old (F, G, J, and
K) mice treated with either exendin-4 or PBS were immunostained with antibodies to insulin (green) and p16 (red) (D, E, F, and G), or to insulin
(green) and Bmi1 (red) (H, I, J, and K). Ex-4, exendin-4. (A high-quality digital representation of this figure is available in the online issue).
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allowed us to test whether upregulation of p16Ink4a in
young Bmi1/ mice would affect -cell expansion. We
treated 6-week-old Bmi1/ mice and their wild-type
littermates daily with exendin-4 for 7 days and quantified
-cell proliferation and -cell mass. After exendin-4 treat-
ment, a twofold increase of -cell mass was observed in
the wild-type mice compared with the PBS-injected con-
trol group (Fig. 5D). In contrast, no difference in -cell
mass was found between exendin-4– and PBS-treated
Bmi1/ mice. To ascertain whether -cell proliferation
was affected in Bmi1/ mice treated with exendin-4, we
quantified -cell proliferation in wild-type and Bmi1/
mice after exendin-4 treatment. We observed a threefold
increase in -cell proliferation after exendin-4 treatment in
wild-type mice, whereas no increase was observed in
Bmi1/ mice (Fig. 5E). These data further underscore
the importance of the age-dependent rise of p16Ink4a levels
in regulating age-dependent decline in -cell proliferation
and -cell mass expansion.
Regenerative capacity of -cell decreases with aging.
To assess the effect of aging on -cell regeneration capac-
ity, we adapted a standard regeneration model that uses a
single injection of STZ to lead to a loss of 	50% of the
-cells (31). We used this model for two reasons: 1) an
increase in -cell proliferation is observed 7 days after STZ
injection that correlates with regeneration of -cell mass,
and 2) the residual -cell mass is sufficient to maintain
blood glucose levels, thus potentially minimizing the role
of hyperglycemia in -cell proliferation and apoptosis.
Young and old mice were subject to a single dose of 90
mg/kg STZ to induce partial loss of -cells, and Ki67- and
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FIG. 5. -Cell mass failed to expand in response to exendin-4 treat-
ment in Bmi1/ mice. A: Protein levels of Bmi1 and p16 in isolated
islets from 6-week-old wild-type and Bmi1/ mice. Data were repre-
sentative of pooled islets from three experiments with 3–5 mice per
group. B: Protein levels of Bmi1 and p16 in Min6 cells transfected with
Bmi1 fused with an NH2-terminal myc tag. C: Schematic representation
of the Ink4a/Arf locus, with blue regions, marked 1–4, indicating the
amplified regions in the ChIP studies (top panel) and ChIP analysis for
the indicated antibodies at the Ink4a/Arf locus in islets isolated from
wild-type (WT) andBmi1/ mice (4 weeks old) (bottom panel). On the
x-axis, “5” indicates binding for the negative control corresponding to
exon 2 in the HoxC13 locus. P values were determined by unpaired
Student’s t test. D and E: Analysis of -cell mass (D) and -cell
proliferation (E) of wild-type and Bmi1/ mice after seven constitu-
tive days’ injection of exendin-4. Values are representative of 5–6
slides spanning the whole pancreas of each mouse and three mice per
group. Error bars indicate SE. *P< 0.05; **P< 0.005. Tub, -tubulin.
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FIG. 4. Expression patterns of p16, p27, and cyclin D2 in wild-type and
Bmi1/ mice. Pancreatic sections from 2-week-old wild-type and
Bmi1/ mice were immunostained with antibodies to insulin (green)
and p16, p27, or cyclin D2 (red) as indicated in the figure. KO,
knockout; WT, wild type. (A high-quality digital representation of this
figure is available in the online issue).
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PCNA-positive -cells were evaluated 7 days later. Both
young and old mice that had received single-dose STZ
administration displayed hyperglycemia (Fig. 6A). A num-
ber of proliferating -cells were observed in young mice
after STZ administration. In contrast, old mice injected
with STZ had limited numbers of Ki67- or PCNA-positive
-cells (Fig. 6B, C, and E). Quantification of Ki67-positive
-cells in young mice after STZ administration revealed a
fourfold increase in proliferating -cells, whereas no dif-
ference was observed in older mice after STZ administra-
tion. Quantification of PCNA-positive -cells showed a
fivefold increase in proliferating -cells in young mice
after STZ administration, whereas no difference was ob-
served in older mice. These data indicate that young mice,
unlike old mice, have the capacity to proliferate and
regenerate -cell mass after -cell destruction.
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FIG. 6. -Cell regeneration capacity is severely diminished in old mice. A: Blood glucose of young and old mice after STZ or sham injection of
vehicle alone. B: Percentage Ki67-positive cells of young and old mice after STZ or sham injection. Values are averaged from four slides for each
mouse and three mice in each group. C: Percentage PCNA-positive cells of young and old mice after STZ or sham injection. Values are averaged
from two slides for each mouse and three mice in each group. D–G: Pancreatic sections from control (D and F) or STZ-administered (E and G)
young (D and E) and old (F and G) mice were immunostained with antibodies to PCNA (red) and to insulin (green). 46-diamidino-2-
phenylindole–stained nuclei appear blue. *P < 0.05; **P < 0.01. (A high-quality digital representation of this figure is available in the online
issue).
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DISCUSSION
The experiments presented here were designed to evalu-
ate whether age plays a role in the proliferative and
regenerative capacity of the pancreatic -cell. We used
three distinct models of endogenous -cell renewal and
regeneration: adaptive expansion associated with insulin
resistance, exendin-4–induced -cell expansion, and the
regeneration of -cells after toxin-mediated ablation. In all
three models, young mice had the capacity to expand or
regenerate -cells, whereas the -cell mass of old mice did
not show similar plasticity. We also show that the age-
dependent decline in the capacity for -cell mass expan-
sion coincides with reduced -cell proliferation. Our data
suggests that age-dependent decline in -cell proliferation
curtails the ability of the endocrine pancreas to expand or
regenerate -cell mass to respond to changes in metabolic
demands, growth factors, or injury.
Our data raise an important issue in assessing therapeu-
tic strategies in diabetes research that are largely carried
out in young mice, when the -cell proliferative and
regeneration capabilities are still retained. It could be
argued that older mice with more limited regeneration
capacity would serve as a better model for assessing
therapies for humans. For instance, the age of NOD mice
in most of the studies could contribute to the success in
the reversal of diabetes in NOD mice but failures in
humans (32,33). It has been suggested that incretin hor-
mone therapy might serve to foster -cell regeneration in
humans with either type 1 or type 2 diabetes, but it is likely
that GLP-1–induced increased -cell mass may not be
achievable in typical middle-aged patients with the capac-
ity for -cell expansion so predictably low in these human
subjects (34).
The plasticity of -cell mass was correlated with -cell
proliferation and the regulation of the Ink4/Arf locus. The
product of the Ink4a/Arf (Cdkn2a) locus, p16Ink4a (a
negative regulator of CDK4 D-type cyclins), is thought to
be involved in aging, and in genome-wide studies it has
linked with type 2 diabetes (35,36). Moreover, the age-
induced increase in p16Ink4a has been shown to limit the
regenerative capacity of -cells with aging (15). Several
studies suggest a role for polycomb group proteins in the
regulation of expression from the Ink4a/Arf locus, and
Bmi1, a key component of the polycomb complex, has
been widely implicated in this process (37,38). We have
correlated -cell proliferation with changes in expression
of Bmi1 and p16Ink4a in -cells that serve as both biological
markers and effectors of aging. Our data suggests that
age-related changes within the -cell may be a significant
contributing factor to reduced tissue homeostasis and
regeneration in older individuals. Whereas the simplest
model is that the Bmi1/p16Ink4a pathway operates in the
-cell to regulate -cell proliferation via CDK4 cyclin D2, it
is possible that this pathway acts in putative stem cells
that lead to regulation of -cell mass. Activation of the
Bmi1 in distinct cell types within the pancreas will shed
light on the compartment that regulates -cell mass.
Our data indicate that age-related changes that lead to
-cell senescence may be a significant contributing factor
to reduced tissue homeostasis and regeneration in older
mice. In fact, these senescence-inducing mechanisms pre-
sumably act to prevent the development of malignancy in
the aging organism, but this protection comes at the cost
of lost proliferative potential (39). However, we need to be
cautious in interpreting experimental data from short-lived
rodents to long-lived humans, where cellular senescence
might be regulated by alternative mechanisms. We suggest
diminished proliferative capacity of -cells is the primary
cause of why -cells in old mice expand less successfully.
It is also worth pointing out that the -cell population is
heterogeneous, and aging may change the composition of
the -cell population (34). Other distinct processes that
may operate in humans to account for diminished regen-
erative capacity with aging include altered stem/progeni-
tor cell function, an increased tendency for apoptosis,
alterations in growth factor profiles, and important
changes in immune responses. It will be crucial in the
future to better characterize these underlying mechanisms
to develop new therapeutic strategies for diabetes because
the progression of diabetes is likely to alter how the
pancreas copes normally with tissue homeostasis. Under-
standing the mechanisms that regulate declining capacity
for -cell expansion with aging is not only important from
the perspective of regeneration, but it also should be taken
into account when selecting donor islets to be used in
cellular therapies.
In summary, we have shown here that the ability to
expand -cell mass in mice declines with age and is
correlated with reduced -cell replication. Furthermore,
we have correlated the age-dependent decline in the
regenerative capacity of -cells with the Bmi1/Ink4/Arf
pathway. The latter pathway might therefore represent a
molecular target in efforts to foster -cell regeneration in
the treatment of diabetes.
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